Journal of Translational Medicine (Nov 2010)

Certolizumab pegol has a different profile from other anti-TNFs, including golimumab, in a variety of in vitro assays

  • Nesbitt A,
  • Fossati G

DOI
https://doi.org/10.1186/1479-5876-8-S1-P37
Journal volume & issue
Vol. 8, no. Suppl 1
p. P37

Abstract

Read online

No abstracts available.